The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells

Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer

(2012) X. Yao et al.   BLOOD

Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma

(2011) D. Buglio et al.   BLOOD

Determinants of Successful CD8 + T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice

(2011) Christopher A. Klebanoff et al.   CLINICAL CANCER RESEARCH

Enhanced Sensitivity to IL-2 Signaling Regulates the Clinical Responsiveness of IL-12-Primed CD8+ T Cells in a Melanoma Model

(2011) D. N. Lisiero et al.   JOURNAL OF IMMUNOLOGY

HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells

(2010) W Song et al.   LEUKEMIA

The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy

(2009) L. Ellis et al.   BLOOD

Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges

(2009) Peter Atadja   CANCER LETTERS

Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824

(2009) D. D. Vo et al.   CANCER RESEARCH

Histone Deacetylase Inhibitors in Cancer Therapy

(2009) Andrew A. Lane et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-Leukemia Activity of MS-275 Histone Deacetylase Inhibitor Implicates 4-1BBL/4-1BB Immunomodulatory Functions

(2009) Bérengère Vire et al.   PLoS One

Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain

(2008) Robert M. Prins et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor

(2008) M. J. Gough et al.   CANCER RESEARCH

Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma

(2008) Sergio A. Quezada et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Transcriptional Modulation Using HDACi Depsipeptide Promotes Immune Cell-Mediated Tumor Destruction of Murine B16 Melanoma

(2008) Takashi Murakami et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY